A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Recruiting now · Phase 1

Conditions studied: Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma, Cutaneous Squamous Cell Cancer, Penile Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Vaginal Squamous Cell Carcinoma, Urethral Squamous Cell Carcinoma

In brief

The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.

Key facts

Study ID
NCT07217171
Run by
EvolveImmune United, Inc
People needed
160
Starts
2025-11-13
Expected to finish
2031-01-29
Last updated by the study team
2026-08-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.